上海莼試生物技術(shù)有限公司
   
菜單 Close 公司首頁 公司介紹 公司動(dòng)態(tài) 產(chǎn)品展廳 證書榮譽(yù) 聯(lián)系方式 在線留言
您當(dāng)前的位置: 網(wǎng)站首頁 > 產(chǎn)品展廳 >抗體 >磷酸化鈣調(diào)節(jié)蛋白-1抗體品牌
產(chǎn)品展廳
磷酸化鈣調(diào)節(jié)蛋白-1抗體品牌
  • 品牌:上海莼試
  • 產(chǎn)地:進(jìn)口、國(guó)產(chǎn)
  • 貨號(hào):CS11875
  • 發(fā)布日期: 2019-01-25
  • 更新日期: 2025-03-14
產(chǎn)品詳請(qǐng)
產(chǎn)地 進(jìn)口、國(guó)產(chǎn)
品牌 上海莼試
保存條件 Store at -20 °C
貨號(hào) CS11875
應(yīng)用范圍 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
CAS編號(hào)
抗體名 Anti-Phospho-Troponin I(Ser23/24)
克隆性
靶點(diǎn) 詳見說明書
適應(yīng)物種 詳見說明書
形態(tài) 詳見說明書
宿主 詳見說明書
亞型 IgG
標(biāo)識(shí)物 詳見說明書
濃度 1mg/1ml%
免疫原 KLH conjugated Synthesised phosphopeptide derived from human Troponin I around the phosphorylation site of Ser23/24

產(chǎn)品訂購(gòu)信息:
英文名稱  Anti-Phospho-Troponin I(Ser23/24) 

中文名稱   磷酸化鈣調(diào)節(jié)蛋白-1抗體品牌 

      Troponin I, cardiac muscle; Full=Cardiac troponin I.


       1mg/1ml

規(guī)   0.1ml/100μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human 

產(chǎn)品類型   一抗 磷酸化抗體  

研究領(lǐng)域     細(xì)胞生物 免疫學(xué) 結(jié)合蛋白

蛋白分子量  predicted molecular weight: 34kDa

       Lyophilized or Liquid

 KLH conjugated Synthesised phosphopeptide derived from human Troponin I around the phosphorylation site of Ser23/24 

       IgG

純化方法   affinity purified by Protein A

儲(chǔ)    0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化鈣調(diào)節(jié)蛋白-1抗體品牌 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

(石蠟切片需做抗原修復(fù)) 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 Calponin, a calmodulin, is a thin filament associated protein that is implicated in the regulation and modulation of smooth muscle contraction. It is capable of binding to actin, calmodulin, troponin C and tropomyosin. Calponin is expressed in smooth muscle and tissues containing significant amounts of smooth muscle. Two isoforms of calponin exist whose molecular weights are 34kDa and 29kDa. Expression of the 29kDa form is primarily restricted to muscle of the urogenital tract. The expression of calponin has also been demonstrated in myoepithelial cells from benign and malignant breast lesions.

Function : Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.

Subunit : Binds to actin and tropomyosin. Interacts with TRIM63. Interacts with STK4/MST1.

Post-translational modifications : Phosphorylated at Ser-42 and Ser-44 by PRKCE; phosphorylation increases myocardium contractile dysfunction (By similarity). Phosphorylated at Ser-23 and Ser-24 by PRKD1; phosphorylation reduces myofilament calcium sensitivity. Phosphorylated preferentially at Thr-31. Phosphorylation by STK4/MST1 alters its binding affinity to TNNC1 (cardiac Tn-C) and TNNT2 (cardiac Tn-T).

DISEASE : Defects in TNNI3 are the cause of familial hypertrophic cardiomyopathy type 7 (CMH7) [MIM:613690]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

Defects in TNNI3 are the cause of familial restrictive cardiomyopathy type 1 (RCM1) [MIM:115210]. RCM1 is a heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.

Defects in TNNI3 are the cause of cardiomyopathy dilated type 2A (CMD2A) [MIM:611880]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. [DISEASE] Defects in TNNI3 are the cause of cardiomyopathy dilated type 1FF (CMD1FF) [MIM:613286]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.

Similarity : Belongs to the troponin I family.

Database links : UniProtKB/Swiss-Prot: P19429.3

Calponin1是一種激動(dòng)蛋白結(jié)合蛋白,是平滑肌特有的一種蛋白,可以與肌動(dòng)蛋白、原肌球蛋白和鈣調(diào)素結(jié)合,具有,主要用于平滑肌和乳腺等組織中的肌上皮細(xì)胞分布的研究。主要表達(dá)于細(xì)胞核.

CULLIN (Cdc53/CUL) Multi-class antibodies規(guī)格: 0.5mg

Anti-CCR-3 細(xì)胞表面趨化因子受體3抗體Multi-class antibodies規(guī)格: 0.1ml

Rhesus antibody Rh PBLD/MAWBP MAWD結(jié)合蛋白抗體 規(guī)格 0.2ml

IL17RD Kit Human 人 IL17RD ELISA配對(duì)抗體 ELISA

TRPM2 英文名稱: 瞬時(shí)受體電位離子通道蛋白/M亞家族抗體 0.2ml

C5a anaphylatoxin 英文名稱: 過敏毒素C5a/補(bǔ)體C5a抗體 0.1ml

Anti-CCR-3 細(xì)胞表面趨化因子受體3抗體Multi-class antibodies規(guī)格: 0.1ml

NPY1R (neuropeptide Y1 receptor) 神經(jīng)肽Y1受體抗原Multi-class antibodies規(guī)格: 0.5mg

Anti-AR 雄激素受體抗體Multi-class antibodies規(guī)格: 0.1ml

Rhesus antibody Rh phospho-ATG3 (Tyr18) 磷酸化自噬相關(guān)蛋白3抗體 規(guī)格 0.1ml

鼠兔通用SABC(HRP)試劑盒 200片 Vector分裝

USF-1 英文名稱: 等上游刺激因子1抗體 0.1ml

DHH 英文名稱: DHH蛋白抗體 0.2ml

Anti-AR 雄激素受體抗體Multi-class antibodies規(guī)格: 0.1ml

Anti-Slc26a5/Prestin/FITC 熒光素標(biāo)記外毛細(xì)胞運(yùn)動(dòng)蛋白/可溶性載質(zhì)轉(zhuǎn)運(yùn)蛋白Slc26a5抗體IgGMulti-class antibodies規(guī)格: 0.2ml

CK19 細(xì)胞角蛋白19抗原Multi-class antibodies規(guī)格: 0.5mg

谷氨酸受體2C抗體 Anti-NR2C/NMDAR2C 0.2ml

Sox9a 英文名稱: 轉(zhuǎn)錄因子sox9a抗體 0.2ml

ESAM 英文名稱: 內(nèi)皮細(xì)胞粘附分子抗體 0.1ml

Rhesus antibody Rh Phospho-p40phox (Thr154) 磷酸化嗜中性粒細(xì)胞胞漿因子4抗體 規(guī)格 0.1ml

CK19 細(xì)胞角蛋白19抗原Multi-class antibodies規(guī)格: 0.5mg

大鼠腦素/腦尿肽(BNP)ELISA試劑盒 ,英文名: BNP ELISA Kit

人S100蛋白(S-100)ELISA檢測(cè)試劑盒HumanSolubleprotein-100,S-100ELISAKit 96T/48T

魚11-酮睪酮(KT)免疫試劑盒 Fish 11-keto Testosterone,KT ELISA Kit

CLIAKitforPAPELISAKit大鼠酸性磷酸酶規(guī)格:48T/96T

水樣品內(nèi)毒素比色法定量檢測(cè)試劑盒20次

ELISAKitflagellin人鞭毛蛋白規(guī)格:48T/96T

大鼠成肌分化蛋白(MyoD)ELISA試劑盒 ,英文名: MyoD ELISA Kit

Rat bladder tumor aigen (BTA) ELISA Kit 大鼠膀胱抗原(BTA)ELISA試劑盒

RatN-terminalprocollagenⅢpropeptide,PⅢNPELISAKit 大鼠Ⅲ型前膠原肽(PⅢNP)ELISA試劑盒 96T/48T 進(jìn)口分裝

CLIAKitforCR(HumanCalretinin)ELISAKit人鈣結(jié)合蛋白規(guī)格:48T/96T

細(xì)胞氧化型谷胱甘肽(GSSG)濃度比色法定量檢測(cè)試劑盒50次

RatCyclin-D2ELISAKit大鼠細(xì)胞周期素D2(Cyclin-D2)ELISA試劑盒規(guī)格:96T/48T

磷酸化鈣調(diào)節(jié)蛋白-1抗體品牌 大鼠毒蕈堿型膽堿受體M1(CHRM1)ELISA試劑盒 ,英文名: CHRM1 ELISA Kit

Human DNA binding protein (DBP) ELISA Kit 人DNA結(jié)合蛋白(DBP)ELISA試劑盒

Ratmaixmetalloproteinase8/Neuophilcollagenase,MMP-8ELISAkit 大鼠基質(zhì)金屬蛋白酶8/中性粒細(xì)胞膠原酶(MMP-8)ELISA試劑盒 96T/48T 進(jìn)口分裝

CLIAKitforD2D(RabbitD-Dimer)ELISAKit兔子D二聚體規(guī)格:48T/96T

細(xì)胞色素P450亞酶2C18(DICLOFENAC)活性高效液相色譜法(HPLC)定量檢測(cè)試劑盒20次

Ratglucocoicoidreceptor,GRELISAKit大鼠糖皮質(zhì)類固醇受體(GR)ELISA試劑盒規(guī)格:96T/48T

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn):

1. 磷酸化鈣調(diào)節(jié)蛋白-1抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件;

3.NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活;

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等;

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性;

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合;

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用;

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

抗體的鑒定:

1磷酸化鈣調(diào)節(jié)蛋白-1抗體品牌 抗體的效價(jià)鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。

2)抗體的特異性鑒定:抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力??贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3)抗體親和力:是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。

 


聯(lián)系方式
手機(jī):13585831301
Q Q:
亚洲精品乱码久久久久久久久久久久,国产精品视频色尤物yw,亚洲AV日韩AV永久无码色欲,亚洲a∨精品永久无码